8:30 am Registration & Coffee

Spotlights Beyond CD47 Targeting to Expand Macrophage Therapy Repertoire

9:25 am Chair’s Opening Remarks

9:30 am Industry Leader’s Fireside Chat: A Roundup of Clinical Development with a Focus on Clinical Validation

  • Carol O’Hear Vice President, Clinical Development, Hematology Franchise Head, Gilead Sciences
  • Sergio Trombetta Senior Principal Scientist, Cancer Immunology & Immune Modulation, Boehringer Ingelheim
  • Leonard Reyno Executive Vice President & Chief Medical Officer, Pionyr Immunotherapeutics


• Unraveling clinical success stories to reaffirm the potential of macrophage-directed therapies and boost
investment in the macrophage space
• Addressing key dosing, safety, and efficacy challenges to accelerate clinical results

10:30 am Exosome Mediated Genetic Reprogramming of Tumor-Associated Macrophages

  • Dalia Burzyn Director, Immuno- Oncology & Inflammation, Codiak BioSciences


• Engineered exosomes allow selective targeting of undruggable transcription factors in macrophages
• exoASO-STAT6 induces reprogramming of tumor-associated macrophages and promotes CD8 T-cell mediated adaptive immune responses
• exoASO-STAT6 shows potent monotherapy activity in several mouse syngeneic models

11:00 am
Morning Refreshments & Speed Networking

11:01 am
Preclinical & Discovery

Determining Optimal Combination Therapies to Enhance Efficacy

12:00 pm Profile of BYON4228, a Selective Pan-Allelic SIRPα Blocking Antibody Designed to Improve Efficacy of Therapeutic Anti-Tumor Antibodies


• BYON4228 potentiates both macrophage- and neutrophil-mediated elimination of hematologic and
solid cancer cells in vitro in the presence of several different tumor-targeting antibodies.
• BYON4228 does not recognize the closely related T-cell expressed SIRPα.
• BYON4228 is well tolerated by cynomolgus monkeys. Clinical studies are planned to start in 2022

12:30 pm The Potency of Macrophage Repolarization as a Monotherapy Approach Versus the Need to Combine with Other Treatments


• Macrophage repolarization sets in motion many arms of the anti-tumor response
• Mechanistic combination potential
• Is successful monotherapy possible, and where would it be most effective?

Clinical & Translational

Exploring Clinical Developments Outside CD47 Targeting

12:00 pm Employing a CAR-Macrophage Approach to Successfully Tackle Solid Tumors

  • Ramona Swaby Vice President, Clinical Development, Carisma Therapeutics


• Preclinical background for the development of Carisma Therapeutics CT-0508
• Clinical development of CAR-macrophage therapy with Carisma Therapeutics CT-0508
• Next steps for the development of Carisma Therapeutics CAR-macrophage therapeutic development

12:30 pm Development of Eganelisib, a First-in-Class PI3Kgamma Inhibitor for Next Generation Macrophage Reprogramming Cancer Immunotherapy


• Discovery of Eganelisib and characterization of MOA
• Summary of Eganelisib clinical development program with a focus on translational data

1:00 pm
Lunch Break & Networking

Utilizing Macrophage Interactions to Enrich Targeting Ability

2:00 pm QPCTL is a Small Molecule Drug Target Modulating the Innate Immune Response


  • Identification of QPCTL as a new target that impacts CD47 and several chemokines
  • Preclinical evaluation of QPCTL inhibition

2:30 pm Allocetra: Off-The-Shelf, Universal, Macrophage Reprogramming Cell Therapy for Life-Threatening Diseases

  • Chen Ankri Head of Clinical & Non-Clinical Pharmacology, Enlivex Therapeutics Ltd


  • Product description and mechanism of action
  • Preclinical and clinical efficacy results – inflammatory indications
  • Preclinical efficacy results in solid tumor models

Driving Clinical Operations to Obtain Smooth Development and Validation

2:00 pm Round Table: Crossing the Bridge into the Clinic: Formulating a Strategic Clinical Plan


  • Formulating a clinical hypothesis to drive research and secure funding
  • Mitigating risk in the clinic to ensure efficiency and smooth clinical development
  • Safeguarding patient access to maintain patient supply and guarantee study enrolment

2:30 pm Exploring Mechanisms Underlying Macrophage-Directed Therapy Resistance in Acute Myeloid Leukaemia

  • Mark Williams Lecturer in Cell & Molecular Biology, Glasgow Caledonian University


  • Examining the reasons behind therapy resistance to identify methods to reverse it
  • Understanding the influence of the tumor microenvironment on resistance to
  • Overcoming resistance to broaden and prolong therapy response in patients

3:00 pm
Afternoon Refreshments and Networking

Exploring Macrophage Applications Beyond Oncology to Uncover Future Indications with Targeting Potential

3:30 pm Treating Lysosomal Storage Diseases Using iPSC-derived Microglia

  • Stefan Irion Senior Vice President & Head of Research, BlueRock Therapeutics


Virtual Presentation

  • Inherited, lysosomal storage diseases (LSDs) are characterized by the pathologic build-up of toxic material in the body’s cells because of a genetic defect resulting in enzyme deficiencies.
  • Microglia, the resident myeloid cells of the brain, are dispersed throughout the brain and microglia progenitors can readily be derived from human induced pluripotent stem cells (hiPSCs); BlueRock identified them as a potential cell therapy for LSDs
  • We show that wildtype donor microglia progenitors can cross-correct the enzymatic deficiency in several LSDs in vitro and in vivo by transferring the missing enzyme to diseased cells


4:00 pm Targeting the Oxidized Macrophage Migration Inhibitory Factor (oxMIF) in Inflammation and its Link to Oncology


  • oxMIF is the disease-related and druggable isoform of the macrophage migration inhibitory factor
  • ON104 is an optimized antibody targeting oxMIF for the treatment of patients with inflammatory conditions
  • oxMIF provides a critical link between inflammation and immuno-oncology

4:30 pm Close of Conference Day Two